Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Invivyd, Inc. - Common Stock
(NQ:
IVVD
)
1.610
+0.230 (+16.67%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Invivyd, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
February 11, 2025
Via
Benzinga
Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025
February 10, 2025
From
Invivyd
Via
GlobeNewswire
These 5 Health Care Stocks Saw The Sharpest Retail Interest Jump Last Week
February 10, 2025
These five small-cap pharma and biotech stocks drew heavy attention on Stocktwits last week, driven by key trial results, FDA updates, and promising drug developments.
Via
Stocktwits
Exposures
Product Safety
Which stocks are experiencing notable movement on Friday?
February 07, 2025
Let's have a look at what is happening on the US markets in the middle of the day on Friday. Below you can find the top gainers and losers in today's session.
Via
Chartmill
(IVVD) - Analyzing Invivyd's Short Interest
February 05, 2025
Via
Benzinga
On Thursday, there are stocks with unusual volume. Let's take a look.
February 06, 2025
Let's explore the current happenings on the US markets on Thursday. Below, you'll find the stocks exhibiting unusual volume in today's session.
Via
Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
February 06, 2025
Via
Benzinga
Here are the top movers in Wednesday's session.
February 05, 2025
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via
Chartmill
Invivyd Announces Partnership with Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of COVID-19: Common, Not A Cold
February 05, 2025
From
Invivyd
Via
GlobeNewswire
Tuesday's session: most active stocks
February 04, 2025
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the most active stocks in today's session.
Via
Chartmill
Unusual volume stocks in Tuesday's session
February 04, 2025
In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look.
Via
Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
February 04, 2025
Via
Benzinga
Why Palantir Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
February 04, 2025
Via
Benzinga
Top movers in Monday's session
February 03, 2025
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.
Via
Chartmill
Discover the most active stocks in Monday's session.
February 03, 2025
Stay updated with the latest market activity on Monday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight.
Via
Chartmill
Keep an eye on the top gainers and losers in Monday's session.
February 03, 2025
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.
Via
Chartmill
Traders are paying attention to the gapping stocks in Monday's session.
February 03, 2025
The market is filled with gapping stocks in Monday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Via
Chartmill
Invivyd Touts Encouraging Data From COVID-19 Antibody Trial, Stock Jumps
February 03, 2025
Invivyd data shows strong potency and prolonged antibody levels in trials. Q4 Pemgarda revenue rose 48% to $13.8 million.
Via
Benzinga
Exposures
COVID-19
Stay updated with the stocks that are on the move in today's pre-market session.
February 03, 2025
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Via
Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
February 03, 2025
Via
Benzinga
Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population
February 03, 2025
From
Invivyd
Via
GlobeNewswire
Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability
February 03, 2025
From
Invivyd
Via
GlobeNewswire
Which stocks are moving after the closing bell on Friday?
January 31, 2025
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Via
Chartmill
Curious about the stocks that are showing activity after the closing bell on Monday?
January 27, 2025
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Via
Chartmill
Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA’s Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised
January 27, 2025
From
Invivyd
Via
GlobeNewswire
What's Going On With COVID-19 Antibody Developer Invivyd Stock On Friday?
January 10, 2025
Invivyd's new data highlights Pemgarda's activity against SARS-CoV-2 XEC and over 75% of variants, with consistent neutralization since Omicron BA.1.
Via
Benzinga
Exposures
COVID-19
12 Health Care Stocks Moving In Friday's Pre-Market Session
January 10, 2025
Via
Benzinga
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC
January 10, 2025
From
Invivyd
Via
GlobeNewswire
Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 14, 2024
From
Invivyd
Via
GlobeNewswire
Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor
November 14, 2024
From
Invivyd
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.